All Resources

The video discusses the management of patient anxiety after positive T1D islet autoantibody results: Guidance on monitoring, education, and psychosocial support. 

The video discusses how advances in insulin delivery have yet to translate into improved population-level glycemic outcomes

Dr Jeremy Pettus explains how to identify type 1 diabetes (T1D) in adults, avoid misclassification as type 2 diabetes (T2D), and interpret islet autoantibodies (IAbs) and C-peptide to support diagnosis and staging. 

Explore the complex autoimmune cascade that leads to beta cell destruction and development of type 1 diabetes.

The Early-stage T1D: Communication Toolkit is a clear, simple resource for healthcare professionals to support effective, age-appropriate communication with individuals undergoing screening for T1D islet autoantibodies or receiving test results.  

Explore how decades of advancements in biomarkers, genetics, and staging frameworks have culminated in our ability to “see” T1D before symptoms emerge.

Explore how diabetic ketoacidosis (DKA) affects people with T1D and their families, and learn why early detection through autoantibody screening can prevent this crisis. 

In this panel, Dr. Stephen Gitelman facilitated the discussion with Prof Loredana Marcovecchio, Prof Holly O’Donnell, and Prof Jacques Beltrand. The speakers discussed the benefits of early detection of T1D in young people and how insights from screening initiatives can inform global programs, strategies for navigating conversations with individuals considering screening, and the importance of beta-cell preservation in the context of current and emerging therapeutic approaches.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform. 
  

Maintaining residual beta-cell function in T1D improves glycemic control, reduces complications, and impacts care and outcomes in people with T1D.

Expert insights on recommendations for T1D screening, including proposed age ranges and opportunities for integration into existing public health touchpoints. 

Appropriate strategies can help support people with early-stage T1D and their families and address anxiety during early T1D monitoring, ensuring optimal engagement and care. 

During the BR1DGE Talks symposium at EASD 2025, experts discussed learnings from the implementation of population-level type 1 diabetes (T1D) screening programs.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.